baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UC UC UC UC UC UC UC UC UC UC UC .../ DE000HC6BB48 /

2024-05-31 9:45:34 AM	Chg.+0.0500	Bid11:03:58 AM	Ask11:03:58 AM	Underlying	Strike price	Expiration date	Option type
3.4400EUR	+1.47%	3.4300 Bid Size: 100,000	3.4400 Ask Size: 100,000	SANOFI SA INHABER ...	122.2137 EUR	2078-12-31	Put

GlobeNewswire 7:05 AM Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD

GlobeNewswire 7:05 AM Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD

GlobeNewswire 7:00 AM Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...

GlobeNewswire 7:00 AM Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with typ...

GlobeNewswire 05-30 Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affa...

GlobeNewswire 05-30 OSE Immunotherapeutics Provides Business and Corporate Update

GlobeNewswire 05-30 Press Release: Sanofi completes acquisition of Inhibrx, Inc.

GlobeNewswire 05-27 Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible ...

GlobeNewswire 05-23 CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

GlobeNewswire 05-21 Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration

GlobeNewswire 05-20 Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...

GlobeNewswire 05-20 Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...

GlobeNewswire 05-20 Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meet...

GlobeNewswire 05-13 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...

GlobeNewswire 05-13 Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...

TeleTrader 05-13 Europe mixed at open as CPI prints loom

GlobeNewswire 05-13 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...

TeleTrader 05-10 Novavax skyrockets 213.5% in premarket, highest in 16 months

TeleTrader 05-10 Novavax soars 39.6% in premarket after Sanofi license deal

GlobeNewswire 05-10 Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVI...

GlobeNewswire 05-09 Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab

TeleTrader 05-09 Europe opens mixed with BoE in focus

GlobeNewswire 05-08 IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire 05-07 Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

GlobeNewswire 05-02 Regeneron Reports First Quarter 2024 Financial and Operating Results

UC UC UC UC UC UC UC UC UC UC UC .../ DE000HC6BB48 /

If you wish to receive reply to your feedback, please provide your email address.